Ryan Jensen, Ph.D


Lynette Sholl, M.D.

This webinar is a recorded presentation of a live broadcast and includes a pre-test, the presentation, handout, and a post-test. Continuing education credit is available for the webinar.

Description: This presentation will introduce the audience to pathways of DNA repair in human cells, in particular, the homologous recombination (HR) pathway which responds to and repairs DNA double-strand breaks (DSBs) during DNA replication. The BRCA1 and BRCA2 genes code for proteins that are key players in the HR pathway and we will discuss their mechanistic roles in HR. We will discuss germ line mutations in the BRCA genes and how to differentiate a pathogenic mutation from a benign polymorphism as well as variants of uncertain significance and the implications for future cancer risk. We will introduce the concept of loss-of-heterozygosity of the wild type BRCA allele in tumors from patients who are germ line carriers of BRCA mutations. We will introduce the idea of synthetic lethality and how PARP inhibitors (PARPi) were discovered to selectively kill BRCA (HR deficient) tumors. Finally, we will speculate on the mechanism of action of PARPi and mechanisms of resistance in both cell lines and patients who have relapsed during PARPi treatment.  

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: October 29, 2021

CE Information:


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

CMLE Credit: The ASCP designates this activity for a maximum of 1.0 Continuing Medical Laboratory Education (CMLE) credit hour. CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

SAM Credit: This activity is approved by the American Board of Pathology for up to 1.0 SAM credit. Physicians should claim only credit commensurate with the extent of their participation in the activity. Learners must pass the post-test with a score of 80% or higher and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available.  If you are seeking continuing education credit for an accrediting board other than the ABP, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement. 

“Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors” is an up-to-date and useful three-part webcast series that will cover: 1. The mechanism of action of PARP inhibitors and the science of Homologous Recombination Deficiency (HRD) testing, 2. Laboratory considerations (from sample acquisition to result reporting) for HRD testing, and 3. Clinical considerations for testing and treatment and the need for genetic counseling.

This program has been supported through educational grants from AstraZeneca & Merck

You may also be interested in:

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
October 29, 2019
Course Objectives
  • Explain homologous DNA repair mechanisms and the mechanism leading to repair deficiency.
  • Discuss BRCA1 AND BRCA2 genes and mutations, including SNPs, and VUS (variants of uncertain significance), and how these may influence cancer risk
  • Discuss BRCA LOH and BRCA mutations as cancer drivers
  • Define the mechanism of action of PARPi (PARP trapping)
  • Describe the principles of synthetic lethality related to PARPi
  • Discuss how tumors (and cells) develop resistance to PARPi
Understanding the BRCA-Dependent DNA Repair Axis for Assessing Cancer Risk and Therapeutic Intervention (CE Available)
Followup and Claiming CE Credit
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
American Medical Association
Continuing Medical Education: 1.00
American Society for Clinical Pathology
CMLE: 1.00
Jensen Presentation
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00